About: Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial
Creator	Abbasian, Ladan Davoudi-Monfared, Effat Hajiabdolbaghi, Mahboubeh Khalili, Hossein Rahmani, Hamid Salehi, Mohamadreza Mir, Saeed Yekaninejad,
Source	MedRxiv
abstract	Objectives: To the best of our knowledge, there is no published study regarding use of IFN beta-1a in the treatment of severe COVID-19. In this randomized clinical trial efficacy and safety of IFN {beta}-1a has been evaluated in patients with severe COVID-19. Methods: Forty-two patients in the interferon group received IFN beta-1a in addition to the standard of care. Each 44 micrograms/ml (12 million IU/ml) of interferon beta-1a was subcutaneously injected three times weekly for two consecutive weeks. The control group received only the standard of care. Primary outcome of study was time to reach clinical response. Secondary outcomes duration of hospital stay, length of ICU stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects and complications during the hospitalization. Results: As primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 +/- 5.8 vs. 8.3 +/- 4.9 days respectively, P=0.95). On day 14, 66.7% vs. 43.6% of patients in the IFN group and the control group were discharged, respectively (OR= 2.5; 95% CI: 1.05- 6.37). The 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Conclusion: Although did not change time to reach the clinical response, adding to the standard of care significantly increased discharge rate on day 14 and decreased 28-day mortality. Clinical Trial Registration ID #IRCT20100228003449N28.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1101/2020.05.28.20116467
has license	medrxiv
sha1sum (hex)	bd3bf69e31fccda1bef7d253fc93c6d38941b02d
schema:url	https://doi.org/10.1101/2020.05.28.20116467
resource representing a document's title	Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial
resource representing a document's body	covid:bd3bf69e31fccda1bef7d253fc93c6d38941b02d#body_text
is schema:about of	named entity 'preprint' named entity 'preprint' named entity 'peer review' named entity 'flu-like symptoms' named entity 'CC-BY-NC-ND 4.0' named entity 'thrombocytopenia' named entity 'Hypersensitivity reaction' named entity 'oxygen' named entity 'preprint' named entity 'preprint' named entity 'IFN' named entity 'gastrointestinal' named entity 'Hypotension' named entity 'medRxiv' named entity 'IFN' named entity 'corticosteroid' named entity 'diarrhea' named entity 'prophylaxis' named entity 'mood swing' named entity 'CC-BY-NC-ND 4.0' named entity 'preprint' named entity 'preprint' named entity 'control groups' named entity 'antiviral effect' named entity 'dyspnea' named entity '1.10' named entity 'COVID-19.' named entity 'medRxiv' named entity 'ritonavir' named entity 'preprint' named entity 'IFN' named entity 'prognosis' named entity 'ARDS' named entity 'adverse effects' named entity 'preprint' named entity 'respiratory rate' named entity 'mmHg' named entity 'fever' named entity 'China' named entity 'diarrhea' named entity 'CC-BY-NC-ND 4.0' named entity 'ritonavir' named entity 'preprint' named entity '95% CI' named entity 'preprint' named entity 'neurologic disorder' named entity 'medRxiv' named entity 'virus' named entity 'acute respiratory distress syndrome' named entity 'randomized trial' named entity 'hydroxychloroquine' named entity 'preprint' named entity 'control group' named entity 'medRxiv' named entity 'medRxiv' named entity 'IFN' named entity 'methyl prednisolone' named entity 'medRxiv' named entity 'organ failure' named entity 'preprint' named entity 'preprint' named entity 'myalgia' named entity 'lopinavir' named entity 'Adverse effects' named entity 'preprint' named entity 'CC-BY-NC-ND 4.0' named entity 'IFN' named entity 'May 30' named entity 'intravenous immunoglobulin' named entity 'peer review' named entity 'antiviral' named entity 'cough' named entity 'cough' named entity 'platelet count' named entity 'transferase' named entity 'IFN' named entity 'preprint' named entity 'IFN'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software